368 related articles for article (PubMed ID: 25483662)
21. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.
Thorner AR; Lemckert AA; Goudsmit J; Lynch DM; Ewald BA; Denholtz M; Havenga MJ; Barouch DH
J Virol; 2006 Dec; 80(24):12009-16. PubMed ID: 17035318
[TBL] [Abstract][Full Text] [Related]
22. The influence of innate and pre-existing immunity on adenovirus therapy.
Zaiss AK; Machado HB; Herschman HR
J Cell Biochem; 2009 Nov; 108(4):778-90. PubMed ID: 19711370
[TBL] [Abstract][Full Text] [Related]
23. Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon.
Tian X; Su X; Li H; Li X; Zhou Z; Liu W; Zhou R
Virus Res; 2011 Sep; 160(1-2):214-20. PubMed ID: 21740937
[TBL] [Abstract][Full Text] [Related]
24. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes.
Khanam S; Rajendra P; Khanna N; Swaminathan S
BMC Biotechnol; 2007 Feb; 7():10. PubMed ID: 17302980
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K
Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691
[TBL] [Abstract][Full Text] [Related]
26. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.
Mast TC; Kierstead L; Gupta SB; Nikas AA; Kallas EG; Novitsky V; Mbewe B; Pitisuttithum P; Schechter M; Vardas E; Wolfe ND; Aste-Amezaga M; Casimiro DR; Coplan P; Straus WL; Shiver JW
Vaccine; 2010 Jan; 28(4):950-7. PubMed ID: 19925902
[TBL] [Abstract][Full Text] [Related]
27. A correlation of measles specific antibodies and the number of plasmacytoid dendritic cells is observed after measles vaccination in 9 month old infants.
García-León ML; Bonifaz LC; Espinosa-Torres B; Hernández-Pérez B; Cardiel-Marmolejo L; Santos-Preciado JI; Wong-Chew RM
Hum Vaccin Immunother; 2015; 11(7):1762-9. PubMed ID: 26075901
[TBL] [Abstract][Full Text] [Related]
28. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
Zhao H; Xu C; Luo X; Wei F; Wang N; Shi H; Ren X
Front Immunol; 2018; 9():335. PubMed ID: 29563911
[TBL] [Abstract][Full Text] [Related]
29. Epitope mapping and characterization of a neutralizing monoclonal antibody against human adenovirus type 3.
Tian X; Li C; Xue C; Li X; Zhou Z; Zhou R
Virus Res; 2013 Nov; 177(2):189-93. PubMed ID: 24018287
[TBL] [Abstract][Full Text] [Related]
30. Impaired humoral responses to subgenus D adenovirusenovirus infections in HIV-positive patients.
Lord A; Bailey AS; Klapper PE; Snowden N; Khoo SH
J Med Virol; 2000 Dec; 62(4):405-9. PubMed ID: 11074466
[TBL] [Abstract][Full Text] [Related]
31. Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery.
Rojas LA; Condezo GN; Moreno R; Fajardo CA; Arias-Badia M; San Martín C; Alemany R
J Control Release; 2016 Sep; 237():78-88. PubMed ID: 27388756
[TBL] [Abstract][Full Text] [Related]
32. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors.
Veron P; Leborgne C; Monteilhet V; Boutin S; Martin S; Moullier P; Masurier C
J Immunol; 2012 Jun; 188(12):6418-24. PubMed ID: 22593612
[TBL] [Abstract][Full Text] [Related]
33. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
Asefa B; Korokhov N; Lemiale F
Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
[TBL] [Abstract][Full Text] [Related]
34. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.
Santra S; Seaman MS; Xu L; Barouch DH; Lord CI; Lifton MA; Gorgone DA; Beaudry KR; Svehla K; Welcher B; Chakrabarti BK; Huang Y; Yang ZY; Mascola JR; Nabel GJ; Letvin NL
J Virol; 2005 May; 79(10):6516-22. PubMed ID: 15858035
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal quantification of adenovirus neutralizing responses in Zambian mother-infant pairs: Impact of HIV-1 infection and its treatment.
Privatt SR; Bullard BL; Weaver EA; Wood C; West JT
Vaccine; 2019 Aug; 37(36):5177-5184. PubMed ID: 31378535
[TBL] [Abstract][Full Text] [Related]
36. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.
Thorner AR; Vogels R; Kaspers J; Weverling GJ; Holterman L; Lemckert AA; Dilraj A; McNally LM; Jeena PM; Jepsen S; Abbink P; Nanda A; Swanson PE; Bates AT; O'Brien KL; Havenga MJ; Goudsmit J; Barouch DH
J Clin Microbiol; 2006 Oct; 44(10):3781-3. PubMed ID: 17021110
[TBL] [Abstract][Full Text] [Related]
37. Induction of Hantaan virus-specific immune responses in C57BL/6 mice by immunization with a modified recombinant adenovirus containing the chimeric gene, GcS0.7.
Li K; Li PY; Wu XA; Zhang L; Liu ZY; Yu L; Zhang L; Cheng LF; Bai WT; Zhang FL; Xu ZK
Int J Mol Med; 2013 Sep; 32(3):709-16. PubMed ID: 23783439
[TBL] [Abstract][Full Text] [Related]
38. Immunization with apoptotic pseudovirus transduced cells induces both cellular and humoral responses: a proof of concept study in macaques.
Koopman G; Beenhakker N; Hofman S; Walther-Jallow L; Mäkitalo B; Mooij P; Anderson J; Verschoor E; Bogers WM; Heeney JL; Spetz AL
Vaccine; 2012 Mar; 30(15):2523-34. PubMed ID: 22314133
[TBL] [Abstract][Full Text] [Related]
39. Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines.
Crosby CM; Nehete P; Sastry KJ; Barry MA
J Virol; 2015 Jan; 89(1):669-75. PubMed ID: 25355873
[TBL] [Abstract][Full Text] [Related]
40. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung.
Croyle MA; Chirmule N; Zhang Y; Wilson JM
J Virol; 2001 May; 75(10):4792-801. PubMed ID: 11312351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
